BCEL

In a report released on August 11, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Atreca (BCEL - Research Report), with a price target of $12.00. The company's shares closed yesterday at $2.74.According to TipRanks, Willey is a 5-star analyst with an average return of 16.5% and a 48.10% success rate. Willey covers the Healthcare sector, focusing on stocks such as Compugen, Cue Biopharma, and Nurix Therapeutics.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atreca with a $15.75 average price target, which is a 474.82% upside from current levels. In a report released on August 9, H.C.
https://www.tipranks.com/news/blurbs/atreca-bcel-receives-a-buy-from-stifel-nicolaus?utm_source=advfn.com&utm_medium=referral